For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

A Vanderbilt researcher has been awarded $6.2 million to study the effect of opioids on the brain.

A groundbreaking study suggests that IBS might be more of a brain issue than a gut disorder. Researchers found that ...

Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...

The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

The recent settlement that would see Purdue Pharma and its owners, the Sackler family, pay $7.4 billion to resolve lawsuits filed by state and local governments across the country is ...

An international team of researchers, led by the University of Glasgow, hopes to find new ways to target opioid addiction ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, ...

Using an innovative and recently validated animal model of IBS, the researchers showed that opioid delta-receptor agonists can ameliorate stress-induced IBS symptoms by acting on the insular cortex of ...

Last week’s settlement that would see Purdue Pharma and its owners, the Sackler family, pay $7.4 billion to resolve lawsuits filed by state and local governments across the country is ...

Irritable bowel syndrome (IBS) is a common digestive disorder with unclear causes, affecting about 10% of the global ...

President Donald Trump's plan to impose tariffs on goods from Mexico, Canada and China is partly aimed at combating the ...